John Whitfield, MD
Gynecology · Fort Worth, TXNPI 1104867324
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $125,718 of the $140,804 with a category attached, or 89.3%. AbbVie accounts for 77.6% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $49,212 and has fallen 85.7% since, to $7,047 in 2025. Among gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 369 payments — averaging $381.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$109K
- Astellas Pharma US Inc$30K
- Lupin Inc.$212
- Mayne Pharma Commercial LLC$196
- Millicent US Inc$187
- Vertical Pharmaceuticals, LLC$125
- plus $1K from 23 others
Across 636 payments — averaging $3573.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$781K
- AbbVie$520K
- Bayer$320K
- GSK$154K
- Organon$141K
- Sumitomo Pharma America, Inc.$91K
- plus $265K from 6 others
What the payments were for
- Consulting fees$5470%
- Speaking & faculty fees$125,71889%
- Travel & lodging$8,3396%
- Food & beverage$6,0864%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 228 | $109,254 |
| Astellas Pharma US Inc | 46 | $29,761 |
| Lupin Inc. | 16 | $212 |
| Mayne Pharma Commercial LLC | 7 | $196 |
| Millicent US Inc | 8 | $187 |
| Vertical Pharmaceuticals, LLC | 7 | $125 |
| Therapeuticsmd, Inc. | 6 | $105 |
| Aspira Women's Health Inc | 5 | $100 |
| Sumitomo Pharma America, Inc. | 5 | $97 |
| Exeltis, USA Inc. | 5 | $88 |
| Daiichi Sankyo Inc. | 4 | $73 |
| Agile Therapeutics, Inc. | 4 | $71 |
| Duchesnay USA Incorporated | 3 | $69 |
| Myovant Sciences Inc. | 3 | $68 |
| Avion Pharmaceuticals | 4 | $63 |
| Coopersurgical, Inc. | 3 | $56 |
| Bayer | 2 | $42 |
| Organon | 2 | $28 |
| Caldera Medical, Inc | 1 | $24 |
| Pfizer | 1 | $22 |
| Scynexis, Inc. | 1 | $22 |
| Vertex | 1 | $21 |
| Meditrina | 1 | $21 |
| Mycovia Pharmaceuticals, Inc. | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Ascend Therapeutics US, LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| AMAG Pharmaceuticals, Inc. | 1 | $15 |
| Minerva Surgical, Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$140,804 in reported general payments places this provider in the 95th percentile of 161 gynecology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 16 | $7,850 |
| ProgesteroneProgesterone, Micronized | 74 | $4,257 |
| Estradiol | 43 | $4,037 |
| Estradiol (Twice Weekly)Estradiol | 14 | $1,298 |
| ValacyclovirValacyclovir Hcl | 34 | $1,063 |
| Famciclovir | 12 | $75 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $29,761 | $7,85016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 gynecology providers in Texas.
Other gynecology in Fort Worth
- Richard FarnamEl Paso$1.2M
- Jessica ShepherdDallas$809K
- Linda LacyEl Paso$627K
- Robert ZurawinHouston$61K
- Charles EubankCorpus Christi$51K
- Tiffany JacksonGarland$50K
- Cynthia Chaparro-KruegerAustin$41K
- Laura SheltonCorpus Christi$22K
- Nicolas XydasHouston$19K
- Scotty HermannWaco$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.